# Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

> **NCT00196586** · PHASE2 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 75 (—)

## Conditions studied

- HIV Infections
- Chronic Hepatitis C

## Interventions

- **DRUG:** Interleukin 2
- **DRUG:** pegylated interferon alpha 2a
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00196586
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 75 (—)
- **Last updated:** 2007-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00196586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00196586, "Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00196586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*